Given the proven role of the STAT3 pathway in PAH, our study suggests that drug repurposing of clinically approved drugs against STAT3 may offer a valuable strategy in rapidly delivering new PAH therapeutics into the clinic. The gene discussed is STAT3; the disease is pulmonary arterial hypertension.